Blood Pressure and Augmentation Index, Body Composition Changes, Bone Metabolism Biomarkers, Cognition, Fatigue Symptom, Fatty Acid Blood Profile, Gastrointestinal Comfort, Inflammation Biomarkers, Joint Pain, Muscle Strength, Quality of Life, Sleep
Conditions
Keywords
Collagen peptides, Middle aged women, Joint pain, Dietary supplements
Brief summary
This study will examine the effects of combining different types of dietary supplements on various aspects of health and wellbeing in middle aged women. The main outcomes of the trial will be aspects of health and wellbeing that middle aged women report as increasingly problematic, such as joint pain, fatigue, sleep, and changes in body composition, strength, and inflammation. Participants will consume the supplement(s) or placebo for 8 weeks, and outcome measures will be assessed before and after supplementation.
Detailed description
Participants will be randomised to receive either collagen (\ 10 g/day) and omega-3 (2 capsules/day) or maltodextrin (\ 10 g/day) and 2 empty capsules for 8 weeks. Participants will first attend a familiarisation visit where consent will be given and cognitive function tests will be practised (letter comparison, backwards digit span test, and stroop color word tests). Participants will complete a 3-day food record diary before attending Visit 2. In Visit 2, participants will complete a range of questionnaires assessing physical activity, quality of life, sleep, menstrual cycle/menopause status and symptoms . Stature and body composition measures will be recorded. Blood pressure, augmentation index, and handgrip strength will be measured. Venous blood samples will be collected for later measures of inflammation, joint health, and fatty acid profile. Joint pain (under 3 conditions) and fatigue will be assessed using a 100mm Visual Analogue Scale. Gastrointestinal comfort will be rated using a Likert scale. Participants will be provided with another food record diary to complete 3 days prior to visit 3, and they will be given their supplements to consume for 8 weeks and a supplement log to track intake of supplements/medication. Visit 3 will occur 8 weeks after Visit 2 and it will follow the same format as Visit 2. Statistical analysis will be performed with linear mixed model and independent t-tests. Sample sizes are based on a prior estimations for these methods of analysis.
Interventions
DIETARY_SUPPLEMENTCollagen peptides and omega-3
Collagen peptides daily for 8 weeks (\~10 g/day) Omega-3 supplement daily for 8 weeks (2 capsules/day)
DIETARY_SUPPLEMENTPlacebo control
Maltodextrin (\~10 g/day) for 8 weeks
Sponsors
Loughborough University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
35 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Female * Age 35 - 65 years old * Healthy, free from known disease * Non-smoker * BMI of 18 - 30 kg/m2 of * Classified as either recreationally physically active (meet the WHO guidelines for physical activity of completing at least 150-300 min moderate-intensity activity or 75-150 min of vigorous-intensity activity a week, plus muscle-strengthening activities 2 or more days a week) OR classified as sedentary (do not meet minimum activity guidelines but do occasional and/or incidental physical activity (e.g., walking to work, household activities))
Exclusion criteria
* Currently have a musculoskeletal injury or diagnosed condition (e.g., cardiovascular disease, osteoarthritis, diabetes, cancer, metabolic syndrome, uncontrolled hypertension, gastrointestinal disease, blood clotting disorder) * Regularly taking prescription medication initiated in the last 3 months or unstable * Have initiated hormone replacement therapy within the last 3 months and/or currently unstable * BMI not between 18-30 kg/m2 * Allergy to ingredients in supplements or standardized breakfasts * Pregnant or breastfeeding, or any other contraindications to consuming study supplements * Lost more than 10% of body mass in past 6 months or plan on trying to lose body mass during trial period * Currently consuming the supplements being investigated and unwilling to stop taking them * Any known cognitive or visual impairments limiting ability to perform cognitive tests * Unwilling to maintain current diet and physical activity levels or exercise and activity levels above recreationally active (e.g., athlete)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Joint pain under 3 conditions as measured by a 100 mm visual analogue scale (VAS) | 8 weeks | Participants will place a vertical line on the VAS (ranging from no pain (0 mm) to unbearable pain (100 mm)) which will be measured and recorded. Participants will complete a separate VAS for each of the 3 conditions: after standing rest, after 5 body weight squats, and in response to pain levels during daily activities in the last week (such as walking, getting up from chairs, exercising). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hand grip strength dynamometry (kg) | 8 weeks | Hand grip strength will be assessed following the Southampton Protocol, where 3 measures will be taken for each hand. |
| Blood pressure (mmHg) | 8 weeks | After 10 minutes of seated rest, 3 blood pressure readings will be taken and recorded using an automated cuff. |
| Fatigue under 2 conditions measured by a 100 mm visual analogue scale (VAS) | 8 weeks | Participants will place a vertical line on the scale (ranging from no fatigue at all (0 mm) to extremely fatigued (100 mm)) which will be measured and recorded. Participants will complete a visual analogue scale for 2 conditions: right now, and during daily activities in the last week (such as walking, getting up from chairs, exercising). |
| Sleep quality measured by an Athens Insomnia Scale | 8 weeks | The Athens Insomnia Scale is an 8-point questionnaire where participants rank different aspects of their sleep (sleep induction, awakenings during the night, final awakening, total sleep duration, overall sleep quality, sense of wellbeing during the day, functioning during the day, and sleepiness during the day) provided that it occurred at least 3 times in the last week from 0 (no issue) to 3 (serious issue). A lower total score indicates better sleep. |
| Simple Sleep Quality Scale | 8 weeks | The simple Sleep Quality Scale asks the following question 'During the past 7 days, how would you rate your sleep quality overall?'. Participants select a number from 0 (terrible) to 10 (excellent). A lower score indicates better sleep. |
| Aortic Augmentation (AP, mmHg) | 8 weeks | Measured using radial artery tonometry |
| Aortic Augmentation Index (AP/PP, %) | 8 weeks | Measured using radial artery tonometry |
| Letter Comparison test of cognitive function | 8 weeks | Measuring reaction time (ms) and accuracy (%) |
| Backwards Digit Span test of cognitive function | 8 weeks | Measuring the longest correct span score (higher score = better working memory) |
| Stroop Colour Word test of cognitive function | 8 weeks | Measuring congruent/incongruent/neutral reaction time (ms) |
| Quality of life assessed by the 36-Item Short Form Survey Instrument (SF-36) | 8 weeks | A total score is calculated as a percentage |
| Gastrointestinal (GI) Comfort measured via a Likert Scale under 3 conditions | 8 weeks | Participants select one option on the Likert scale ranging from 1 (no GI discomfort) to 4 (lots/frequent/extreme GI discomfort). There is a Likert Scale for each of the following conditions: GI discomfort right now, GI discomfort frequency in the last 8 weeks, and GI discomfort severity in the last 8 weeks. |
| Menstrual cycle/menopause symptom questionnaire | 8 weeks | The questionnaire assesses 12 common menstrual cycle/menopause symptoms. Participants rate the severity (0 = none, to 3 = severe) and frequency (0 = never, to 3 = often) of these symptoms. A higher score indicates worse menstrual cycle/menopause symptoms |
| Fatty acid blood profile | 8 weeks | — |
| Body mass (kg) | 8 weeks | — |
| Fat mass (kg) | 8 weeks | Measured in kilograms and as a fat percentage (%) |
| Fat free mass (kg) | 8 weeks | — |
| Skeletal muscle mass (kg) | 8 weeks | — |
| Body mass index (BMI, kg/m2) | 8 weeks | Calculated as body mass divided by height squared |
| Total body water | 8 weeks | Measured as total body water (L) |
| Total Body Water | 8 weeks | Calculated total body water percentage (%) |
Countries
United Kingdom
Contacts
CONTACTTom Clifford Dr Clifford
Outcome results
None listed